The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...

DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...

This week, Tandem Diabetes Care’s t:slim X2 insulin pump and Control-IQ algorithm made headlines as they became the first to integrate with Dexcom’s G7 sensor to create an artificial pancreas system.

Dexcom announced that its G7 diabetes sensor can now link directly to a user’s Apple Watch, allowing them to track their glucose readings in real-time even if their iPhone isn’t nearby. According to ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

The device is similar to existing prescription CGMs. Users pair the wearable sensor with an application, put it on their arm and receive a continuous stream of glucose data on their smartphone or ...

Tandem Diabetes Care, Inc.’s TNDM Mobi insulin pump with Control-IQ technology is now fully compatible with both Dexcom’s DXCM G7 and G6 Continuous Glucose Monitoring (“CGM”) Systems. The world’s ...

Q4 2025 Management View Jacob Leach, President, CEO & Director, marked his first call as CEO by outlining three strategic priorities: "We will be the premier glucose sensing solution for all," ...

New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.